Trade Summary

1 week ago, Turtle Cameron, serving as Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 15,000 shares at $95.51 per share, for a total transaction value of $1,432,705.05. Following this transaction, Turtle Cameron now holds 567,540 shares of SYRE.

This sale represents a 2.57% decrease in Turtle Cameron's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, August 3, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, August 6, 2026 (accepted Aug 5, 9:31 PM ET), 3 days after the trade was made.

Spyre Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.